ARGX's FB102 achieves its primary endpoint in a phase II celiac disease study, paving the way for la

Evercore ISI Group analyst Gavin Clark-Gartner maintains argenx (NASDAQ:ARGX) with a Outperform a

argenx shares tumble 12% after discontinuing its late-stage Sjogren's disease study, while positive

argenx shares fell after halting its Phase 3 Sjögren's trial, but the selloff appears to overstate t

Baird analyst Colleen Kusy maintains argenx (NASDAQ:ARGX) with a Neutral and lowers the price tar

argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 10.42% on an annualized ba

ARGX share price fell sharply after a futility finding resulted in the discontinuation of a pending

Halozyme wins a Dutch court order blocking Merck's Keytruda SC in eight European markets, strengthen

Shares in argenx SE (NASDAQ:ARGX) fell nearly 15% in New York on Thursday after it discontinued a la

U.S. stocks fell Thursday as Nasdaq slid 150+ points; energy rallied, healthcare dropped. PepsiCo be

Argenx SE (NASDAQ:ARGX) on Thursday delivered mixed clinical updates, announcing positive Phase 2 tr

Argenx announced Phase 2 success for FB102 in celiac disease while halting its Phase 3 UNITY study i

U.S. stock futures were lower this morning, with the Dow futures falling around 450 points on Thursd

U.S. stock futures fell, with Dow futures down 450 points. Argenx sank 8.7% after a Sjögren’s trial

Gainers Profound Medical (NASDAQ:PROF) shares moved upwards by 21.5% to $6.9 during Thursday's

Argenx said on Thursday it had discontinued a late-stage study of its efgartigimod ​drug in adults w

The stock was down 18%, wiping out year-to-date gains after the biotech stopped a late-stage clinica

Applied Digital shares rise after Q1 revenue and loss beat estimates; Xiao-I and iPower lead gainers

Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p=0.0176)First Phase 2 evi

Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p= 0.0176 ) First Phase 2

October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a glo

Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today annou

Integrated Wealth Concepts LLC lowered its stake in shares of argenex SE (NASDAQ: ARGX) by 94.0% dur

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider

This biotech stock could soar 30% or more over the next 12 months if some analysts are right.

argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 14.22% on an annualized ba